Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has earned a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $61.0833.

A number of brokerages recently weighed in on JANX. Truist Financial initiated coverage on shares of Janux Therapeutics in a research note on Wednesday, September 10th. They issued a “buy” rating and a $100.00 target price on the stock. UBS Group restated a “buy” rating and set a $57.00 price objective on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a report on Wednesday, October 8th. Barclays reduced their target price on Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 17th. Finally, Wedbush restated an “outperform” rating and set a $45.00 price target (down previously from $76.00) on shares of Janux Therapeutics in a research report on Tuesday, December 2nd.

Insider Activity at Janux Therapeutics

In related news, insider Thomas Diraimondo sold 2,505 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $34,393.65. Following the transaction, the insider directly owned 124,425 shares of the company’s stock, valued at approximately $1,708,355.25. This trade represents a 1.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO David Alan Campbell sold 8,072 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $110,828.56. Following the completion of the sale, the chief executive officer directly owned 284,982 shares of the company’s stock, valued at approximately $3,912,802.86. This represents a 2.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 42,364 shares of company stock worth $972,185 in the last quarter. 29.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in Janux Therapeutics by 10.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock worth $59,074,000 after purchasing an additional 227,676 shares during the period. Orbimed Advisors LLC grew its stake in shares of Janux Therapeutics by 45.9% during the third quarter. Orbimed Advisors LLC now owns 1,766,100 shares of the company’s stock valued at $43,163,000 after buying an additional 555,800 shares during the last quarter. Readystate Asset Management LP increased its holdings in shares of Janux Therapeutics by 38.0% in the third quarter. Readystate Asset Management LP now owns 960,379 shares of the company’s stock worth $23,472,000 after buying an additional 264,423 shares during the period. Geode Capital Management LLC lifted its stake in shares of Janux Therapeutics by 15.5% in the 2nd quarter. Geode Capital Management LLC now owns 902,312 shares of the company’s stock valued at $20,845,000 after acquiring an additional 121,403 shares during the last quarter. Finally, Prosight Management LP lifted its stake in shares of Janux Therapeutics by 1.3% in the 3rd quarter. Prosight Management LP now owns 865,350 shares of the company’s stock valued at $21,149,000 after acquiring an additional 11,446 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Down 2.2%

Janux Therapeutics stock opened at $13.45 on Wednesday. The stock has a market cap of $808.72 million, a price-to-earnings ratio of -8.00 and a beta of 2.88. The business has a 50-day simple moving average of $21.91 and a 200 day simple moving average of $23.62. Janux Therapeutics has a 52 week low of $13.26 and a 52 week high of $61.59.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.21. The business had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $3.07 million. On average, research analysts anticipate that Janux Therapeutics will post -1.38 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.